BridgeBio Pharma, Inc.

Pharmaceutical Preparations·PALO ALTO, CA·FY end 12/31·CIK 1743881

Board of Directors

12 members · 10 independent · FY 2025

Director	Role	Tenure	Age	Committees	Indep.	Annual fees
Randal W. Scott	Director	—	—	Audit		—
Eric Aguiar, M.D.	Director	6y	—	Audit		—
Jennifer E. Cook	Director	6y	—	Comp		—
Andrea J. Ellis	Director	4y	—	Audit		—
Fred Hassan	Lead Independent Director	4y	—	Comp		—
Ali J. Satvat	Director	9y	—	CompNCG		—
Neil Kumar, Ph.D.	CEO and Director	10y	—	—	—	—
Charles Homcy, M.D.	Lead Director	7y	—	—	—	—
Douglas A. Dachille	Director	4y	—	AuditNCG		—
Ronald J. Daniels	Director	6y	—	Comp		—
Andrew W. Lo, Ph.D.	Director	5y	—	NCG		—
Heidi Valantine	Director	—	—	NCG		—

10-K Item 1A — YoY changes

Need at least two years of 10-K filings to compute. Will populate once both this year's and last year's 10-Ks have been ingested.

Clawback, anti-hedging, stock ownership, and related-party policies will populate from extracted proxy sections.